CPhI Online is the largest global marketplace in the pharma ingredients industry
FDA Initiates the Secure Supply Chain Pilot Programme to Enhance Security of Imported Drugs
FDA is announcing the initiation of the Secure Supply Chain Pilot Program to enhance the security of imported drugs. In August 2013, FDA published a notice in the Federal Register (78 FR 51192) to solicit companies to voluntarily submit applications for participation in this 2-year programme. Thirteen prequalified companies have now been designated to take part, and will receive expedited entry for the importation of up to five selected drug products into the US.
The goal of the programme is to enable FDA to evaluate resource savings that will allow the agency to focus imports surveillance resources on preventing the entry of high-risk drugs that are the most likely to compromise the quality and safety of the US drug supply.
“By creating incentives for manufacturers to adopt best practices for supply chain integrity, we can enhance the quality and safety of imported drugs,” said Carol Bennett, acting director of the Office of Compliance in the FDA’s Center for Drug Evaluation and Research. “The programme also allows FDA to focus resources on the areas with the greatest potential risk to consumers.”
During these next 2 years, FDA will evaluate the programme’s effectiveness at enhancing imported drug compliance with FDA regulations and the security of the drug supply chain. If the FDA determines the programme to be effective, a more permanent programme may be established and possibly extended to additional participating companies.
The prequalified companies accepted into the programme that will receive expedited entry, are the following:
• AbbVie Inc.
• Allergan, Inc.
• Astellas US Technologies, Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• GE Healthcare Inc.
• GlaxoSmithKline LLC
• Merck Sharp & Dohme Corporation
• Mylan Pharmaceuticals Inc.
• Novartis Pharmaceuticals Corporation
• Pfizer, Inc.
• Teva Pharmaceutcials USA, Inc.
• Watson Laboratories, Inc.
Each of the 13 companies met multiple participation conditions, including
• committing to comply with requirements of the Food, Drug, and Cosmetics Act (FDCA)
• having a validated secure supply chain protocol per the US Customs and Border Protection’s Customs-Trade Partnership Against Terrorism (C-TPAT) program
• having a plan in place to quickly correct potential problems FDA identifies regarding importation of specific products
• having effective recall and corrective action plans in place
• maintaining control over their drugs from the time of manufacture abroad through entry into the US.
This second facility gives the company a significant power multiplier for export capacity and geographical reach
News CPhI Discover: Remote excipient audits are on the increase, but we must do more to develop novel excipientsAhead of the session, Value Added Excipients to Unlock the Potential of APIs, at CPhI Discover on Thursday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Dr Iain Moor...
Need clarity on determining your QA from your QbD and your cGMPs? You’re not alone! In our new Pharma Explained series from CPhI, we bring you clear cut definitions from industry experts on a myriad of Pharma Terms, delivered in bitesize video presenta...
News Former FDA Commissioner lays out roadmap for building out excess capacity to deal with pandemic situationsDr Scott Gottlieb shares insights into COVID-19 vaccine development, the upcoming US election and pharma pricing at the CPhI Festival of Pharma
Inspection conducted remotely using video-conferencing and an online private document sharing platform.
Decision clears legal pathway to expand access for patients living with multiple sclerosis in markets across Europe.
The pandemic that has swept over the world in 2020 has caused huge disruption to the European pharmaceutical industry's regulatory procedures and supply chain management. But the crisis has also provided a platform for a learning process for the sy...
The European Medicines Agency's human medicines committee (CHMP) has recommended the suspension of European marketing authorizations of generic medicines tested by Panexcell Clinical Laboratories at its site in Mumbai, India, citing irregularities in h...
Position your company at the heart of the global Pharma industry with a CPhI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPhI events
An easy-to-use platform with a detailed dashboard showing your leads and performance